Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078558 | 0.87 | NAMPT (0.56) | NAMPTTDP1RAB9AKDM4EMEN1 | |
| SCHEMBL7081264 | 0.86 | MEN1 (0.69) | TDP1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL30182179 | 0.85 | NAMPT (0.56) | NAMPTTDP1NPSR1MAPTHDAC1 | |
| SCHEMBL23898926 | 0.81 | NAMPT (0.57) | NAMPTTDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23899245 | 0.81 | NAMPT (0.72) | NAMPTTDP1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL6795009 | 0.81 | MTTP (0.55) | NAMPTKDM4EHDAC1 | |
| SCHEMBL23898927 | 0.80 | NAMPT (0.58) | NAMPTTDP1KDM4ENPSR1MAPT | |
| SCHEMBL6816843 | 0.79 | KMT2A (0.55) | TDP1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL4922883 | 0.79 | NAMPT (0.63) | NAMPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL2012264 | 0.78 | NAMPT (0.58) | NAMPTTDP1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-28 | — | — | US | disclosed |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | HAVCR2, CCR6, CXCR6 | NAMPT 3260/4885TDP1 452/4885SMN1; SMN2 4566/4885 |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | CCR6, HAVCR2, BCOR | NAMPT 3999/4885TDP1 1349/4885SMN1; SMN2 4485/4885 |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | TK1, TPMT, CXCR6 | NAMPT 4031/4885TDP1 505/4885SMN1; SMN2 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.